SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Melania memes are digital collectibles intended to function as an expression of support for and engagement with the values embodied by the symbol MELANIA

Melania Trump

The tokens steep decline from its launch highs has renewed debate over whether it was a Trump-family pump-and-dump, with traders citing alleged insider profits, weak utility, and heavy losses among holders. A small minority remains bullish on a speculative meme-coin rebound, but the dominant reaction is bearish and dismissive.

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Kura is drawing attention after CEO Troy Wilson disclosed another open-market purchase of 100,000 shares, which traders view as a strong confidence signal and a potential catalyst for short covering. Discussion also highlights improving KOMZIFTI launch traction and upcoming frontline AML and darlifarnib data, though some investors remain cautious about valuation, cash burn, and the stocks recent weakness.

Air Canada engages in the provision of airline transportation services. Its services cover full-service airline, scheduled passenger and cargo services, serving more than two hundred airports on six continents. It operates through the following geographical segments: Canada, U.S. Transborder, Atlantic, Pacific, and Other. The company was founded on April 11, 1936 and is headquartered in Saint-Laurent, Canada.

Air Canada Inc. - Ordinary Shares (Voting and Variable Voting)

Air Canada Inc.

Air Canadas monetization of a minority stake in Aeroplan, combined with stronger-than-expected quarterly results, has driven attention as traders focus on the loyalty programs implied valuation, debt repayment and planned share buybacks. The community is broadly bullish on the value-unlocking potential and strong travel demand, though some remain cautious about fuel costs, rising expenses and the companys reported operating loss.

Salesforce, Inc. engages in the design and development of cloud-based enterprise software for customer relationship management. Its solutions include sales force automation, customer service and support, marketing automation, digital commerce, community management, collaboration, industry-specific solutions, and salesforce platform. The firm also provides guidance, support, training, and advisory services. The company was founded by Marc Russell Benioff and Parker Harris in 1999 and is headquartered in San Francisco, CA.

Salesforce Inc

A strong second-quarter earnings report, raised outlook, and expanded Anthropic partnership through Claudeforce have fueled a sharp Salesforce rally and renewed optimism that AI can monetizeand augment rather than replaceenterprise software. Bulls view the move as a break from the SaaSpocalypse narrative, while skeptics argue the reaction is overextended and that buybacks, acquisitions, and still-muted organic growth weaken the case for sustained gains.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A bearish BMF short report questioning SELLASs REGAL Phase 3 trial design, survival assumptions, dilution and valuation triggered the selloff, despite no reported adverse clinical update. Traders are divided between viewing the report as a self-interested short thesis and focusing on the pending 80th-event announcement and REGAL topline data as the decisive catalysts.

Sovereign frontier cloud for AI that builds  AI agents are starting to build and operate real software. Agentic organizations are starting to coordinate people, code, data, payments, and governance. Both need a cloud that is sovereign, tamperproof, and always on.  The Internet Computer is that cloud.  Built on more than USD 500 million in R&amp;D, ICP uses advanced blockchain technology and cryptography to run entire software systems end-to-end on the network: websites, apps, services, data, payments, and governance. Code and data are protected by the protocol, replicated across independent nodes, and cannot be silently changed by a cloud provider, backend operator, or attacker.  Cloud engines make this infrastructure sovereign. They let organizations run ICP-powered compute across chosen providers, locations, and jurisdictions while keeping the same tamperproof and always-on guarantees of the network.  This is the real demand ICP serves: sovereign frontier cloud for AI agents and agentic organizations. Agents can build and update software. Organizations can run rules, assets, and governance as verifiable systems. The result is software that stays online, keeps its data, and remains under the control of its owners.  Developers and AI agents can build on the Internet Computer with any AI assistant using the ICP skill library at skills.internetcomputer.org, or by creating apps through conversation with Caffeine AI.  Computation on ICP is paid for by converting $ICP into cycles. $ICP is also used for staking and governance through the Network Nervous System.

Internet Computer

Attention is centered on DFINITY/ICPs work with the UNDP to explore sovereign cloud and AI infrastructure, including government pilots and Pakistan-related deployments. Traders view this as validation of ICPs decentralized cloud and AI strategy, though skeptics note the initiatives remain pilots and question whether they will translate into near-term adoption, revenue, or stronger price performance.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Updated HARMONi Phase 3 overall-survival data for ivonescimab, showing a more consistent benefit across Western and Asian patients, has renewed attention ahead of the FDAs November decision. Traders remain divided over whether the survival results satisfy the FDAs statistical requirements, while concerns about dilution and funding needs weigh on sentiment.

ImmunityBio, Inc. is a clinical stage immunotherapy company. It develops next generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate and adaptive immune systems to create long term immunological memory. ImmunityBio was founded by Patrick Soon-Shiong in 2014 and is headquartered in San Diego, CA.

ImmunityBio Inc

Completion of Anktivas first German labeling and packaging run has fueled attention around ImmunityBios European commercialization and possible follow-on approvals in the UAE and Saudi Arabia. Traders are divided between viewing the rollout and potential lymphopenia/all-cancer expansion as major growth catalysts and questioning near-term revenue, valuation, and recurring short-term selloffs.

Tesla, Inc. engages in the design, development, manufacture, and sale of electric vehicles and energy generation and storage systems. It operates through the Automotive and Energy Generation and Storage segments. The Automotive segment includes the design, development, manufacture, sale, and lease of electric vehicles as well as sales of automotive regulatory credits. The Energy Generation and Storage segment is involved in the design, manufacture, installation, sale, and lease of solar energy generation, energy storage products, and related services and sales of solar energy systems incentives. The company was founded by Jeffrey B. Straubel, Elon Reeve Musk, Martin Eberhard, and Marc Tarpenning on July 1, 2003 and is headquartered in Austin, TX.

Tesla Inc

Anticipation of Teslas upcoming Cybercab/robotaxi rollout is driving discussion, with bullish traders expecting autonomy, robotics and energy-storage growth to improve the companys trajectory. Skeptics argue the service remains a limited, supervised pilot and question Teslas valuation, EV demand and ability to compete with established autonomous-vehicle operators; trading is also characterized by heavy options activity and volatility around Federal Reserve commentary.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels completed Australian Strategic Materials acquisition and broader mine-to-magnet expansion are driving attention, adding rare-earth metals and alloy capacity to its uranium and White Mesa operations; traders view the move as strengthening Western critical-minerals and defense supply chains. Bullish investors focus on ASM integration, planned VAC acquisition, heavy rare-earth production and nuclear demand, while skeptics point to execution risk, weak price action and persistent selling.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

AbbVies acquisition of Apogee Therapeutics is driving attention, with traders focusing on the deals potential to strengthen its immunology and respiratory pipeline. Debate centers on the strategic value of the purchase versus added debt, dilution, and the long timeline to earnings contribution, alongside broader healthcare-sector rotation and bullish technical momentum.

AbbVie Seeks EU Nod for Subcutaneous Skyrizi in Crohn's Disease

ABBV seeks EU approval for a subcutaneous Skyrizi induction option in Crohn's disease, potentially adding convenience for patients.

FDA Nods Lilly-Roche's Alzheimer's Blood Test: Healthcare ETFs to Track Now 

 FDA clearance of Lilly and Roche's Alzheimer's blood test highlights a growing diagnostics market and four healthcare ETFs to watch.

AbbVie Submits Regulatory Application to EMA for SKYRIZI (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease

AbbVie Submits Regulatory Application to EMA for SKYRIZI (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active Crohn's Disease AbbVie Submits Regulatory Application to EMA for SKYRIZI (risankizumab) Subcutaneous Induction for Adults with Moderately to Severely Active...

If You Invested $100 In AbbVie Stock 10 Years Ago, You Would Have This Much Today

AbbVie (NYSE:ABBV) has outperformed the market over the past 10 years by 1.74% on an annualized basis producing an average annual return of 15.14%. Currently, AbbVie has a market capitalization of $468.74 billion.read more...

Billionaire Ken Griffin Increased His Stake in This Dividend King by 547% in Q2. Wall Street Thinks It's Still a Buy.

Key PointsThe hedge fund manager bought some 2.7 million shares of AbbVie stock in the second quarter...

How Did ABBV's Oncology Sales Hold Up in Q2 Amid Imbruvica Headwinds?

AbbVie's oncology sales fall 2.4% in Q2 as Imbruvica declines, while Venclexta and newer drugs help offset the pressure.

LLY vs. ABBV: Which Stock Has the Stronger Growth Prospects?

Lilly and AbbVie bring different growth drivers, pipelines and risks to the table. See which drugmaker offers the more compelling 2026 upside.

RGNX Stock Slumps 25% on FDA Clinical Hold for RGX-121 Gene Therapy

REGENXBIO stock plunges 25% after the FDA places a clinical hold on RGX-121 for MPS II, following asymptomatic spine MRI findings in five participants.

Is SYRE a Buy Now as Clinical Catalysts Clash With Valuation Risk?

Spyre has a broad clinical pipeline and cash runway, but elevated valuation makes upcoming readouts critical to its investment case.

Can Spyre's SPY772 HS Study Broaden Its Growth Story Beyond Core IBD?

SYRE expands into HS with SPY772, testing whether dual-pathway inhibition can strengthen outcomes in SKYLIGHT.

• Reported GAAP EPS of $2.03 up 290.38% YoY
• Reported revenue of $16.99B up 10.16% YoY
• AbbVie is updating its 2026 adjusted diluted EPS guidance range from $13.91 - $14.11 to $13.87 - $14.07, reflecting an anticipated $0.14 dilutive impact from the proposed acquisition of Apogee Therapeutics.

AbbVie faces significant declines in its Humira and Imbruvica portfolios, while the proposed Apogee Therapeutics acquisition introduces execution, integration, and clinical development risks that could impact future operational results.

AbbVie achieved robust revenue growth in its immunology and neuroscience portfolios, while the strategic acquisition of Apogee Therapeutics bolsters the company's long-term pipeline and immunology leadership position.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

SLS Stock Heads For Worst Month In Over 2 Years — But Retail Bulls ‘Hold’ For AML Readout And Buyout Hopes

Equity

Bullish Sentiment

Track ABBV stock price, charts, news and real-time market activity on Stocktwits. Join the ABBV message board to follow investor discussions, retail trader sentiment, bullish and bearish signals around AbbVie Inc stock.

ABBV Stock Price Today - Abbvie Inc News, Charts, Retail Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a positive week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Fiscal Period	Estimated	Reported	Surprise	Result
Q3 '26	$3.86	--	--	N/A
Q2 '26	$3.60	$3.65	1.40%	BEAT
Q1 '26	$2.59	$2.65	2.23%	BEAT
Q4 '25	$2.65	$2.71	2.15%	BEAT
Q3 '25	$1.77	$1.86	5.32%	BEAT

Feed

News

Sentiment

Earnings

NewFutures

Fundamentals

Info

Latest Earnings Results: Q2 '26

Historical Earnings